Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

751.30 -8.46 (-1.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 322,878
Open 760.30
Bid (Size) 748.80 (1)
Ask (Size) 765.63 (1)
Prev. Close 759.76
Today's Range 751.01 - 764.39
52wk Range 538.01 - 800.48
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 Value Stocks Worth Buying at These 52-Week Highs
While these value stocks to buy are trading near their 52-week highs, they still have plenty of gas left in the tank for investors. 
Via InvestorPlace
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
+4.28%
+4.28%
1 Month
+0.64%
+0.64%
3 Month
+2.02%
+2.02%
6 Month
+9.74%
+9.74%
1 Year
+8.47%
+8.47%

More News

Read More
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Via Talk Markets
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today
Via Benzinga
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
Via Investor's Business Daily
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
How Is The Market Feeling About Regeneron Pharmaceuticals?
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Via Benzinga
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Via Talk Markets
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
Via The Motley Fool
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
Via Benzinga
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Via Investor's Business Daily
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Via MarketBeat
3 More Mid-Cap Biotechs The Street Sees Doubling
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.